New FDA-cleared AI tool could help predict if breast cancer will return

Food and Drug Administration has cleared an artificial‑intelligence system that estimates whether a patient’s hormone‑receptor‑positive, HER2‑negative breast cancer will return. The clearance means clinicians can now receive an MRI‑derived recurrence risk score, and patients gain a data‑driven outlook on future treatment decisions. SimBioSys, the developer behind TumorSight Risk, secured the approval, positioning the company for market entry while oncologists anticipate a new tool for personalized care. OncLive reported the FDA clearance of TumorSight Risk, and MobiHealthNews confirmed SimBioSys’s regulatory win.

ABC News highlighted the same development in a breaking‑news story. The tool’s algorithm was trained on a supercomputer, according to News‑Medical, to improve diagnostic reliability. Newswise described a new approach that gauges AI reliability for breast‑cancer diagnosis, while a University of Chicago clinical trial described by NBC 5 Chicago uses AI to tailor treatment plans for individual patients. WTKR and Bioengineer.org warned that AI mammography advances can falter when training datasets lack diversity, and that current tools still require refinement.

The coverage therefore stresses that clinicians should interpret the recurrence score alongside conventional assessments until broader validation is achieved. Patients could see more personalized follow‑up schedules and insurers may adjust coverage based on AI‑driven risk stratification, while manufacturers hope to expand the cleared indication to other breast‑cancer subtypes. The next steps outlined in the coverage include monitoring outcomes from the University of Chicago trial and tracking additional FDA evaluations of AI reliability metrics. Future reporting will likely focus on data‑set diversity improvements and real‑world performance of TumorSight Risk.